Nasdaq · Healthcare
Universe Pharmaceuticals INC (UPC)
As-reported financials and recent SEC filings for Universe Pharmaceuticals INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$17.86B
Net income
$-3.67B
Net margin
-20.6%
Diluted EPS
$-8.06
ROE
-6.5%
P/E (TTM)
—
Market cap
$1.9M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $17.86B | $23.02B | $32.31B | $40.1M | $48.0M |
| Gross profit | $6.30B | $6.07B | $10.32B | $21.9M | $25.3M |
| Operating income | $-2.92B | $-8.02B | $-3.97B | $-7.0M | $13.6M |
| Net income | $-3.67B | $-8.73B | $-6.58B | $-7.9M | $11.3M |
| Diluted EPS | $-8.06 | $-19.00 | $-16.50 | $-19.83 | $28.42 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
6-K2026-06-26
View on EDGAR →42026-05-21
View on EDGAR →SCHEDULE 13D2026-05-21
View on EDGAR →6-K2026-05-14
View on EDGAR →6-K2026-04-16
View on EDGAR →32026-03-18
View on EDGAR →32026-03-18
View on EDGAR →32026-03-18
View on EDGAR →Go deeper on UPC
Search Universe Pharmaceuticals INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.